24ξ-Squalamine | 184851-39-6

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: 24ξ-Squalamine
• 英文别名: squalamine；[(6R)-6-[(3S,5R,7R,8R,9S,10S,13R,14S,17R)-3-[3-(4-aminobutylamino)propylamino]-7-hydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]-2-methylheptan-3-yl] hydrogen sulfate
• CAS: 184851-39-6
• 化学式: C₃₄H₆₅N₃O₅S
• 分子量: 627.973
• InChiKey: UIRKNQLZZXALBI-OVOJGICBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  43
• 可旋转键数：
  16
• 环数：
  4.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  142
• 氢给体数：
  5
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  24ξ-Squalamine 、 3-[18F]fluoropropyl p-tosylate 以 N,N-二甲基甲酰胺 为溶剂， 反应 0.33h， 生成
  参考文献：
  名称：

  Shiue, C.-Y.; Shiue, G. G.; Alavi, A. A., Journal of labelled compounds and radiopharmaceuticals, 2001, vol. 44, p. S391 - S392

  摘要：

  DOI：
• 作为产物：
  描述：

  7α-(Benzyloxy)-3β-(tetrahydropyranyloxy)-5α-cholan-24-al 在 palladium on activated charcoal 吡啶 、 咪唑 、 盐酸 、 pyridine-SO3 complex 、 3 A molecular sieve 、 氢气 、 dipyridine chromium trioxide 、 sodium cyanoborohydride 、 三氟乙酸 、 magnesium bromide 作用下， 以 四氢呋喃 、 乙醚 、 乙醇 、 二氯甲烷 、 氯仿 为溶剂， 25.0~40.0 ℃ 、379.21 kPa 条件下， 反应 86.25h， 生成 24ξ-Squalamine
  参考文献：
  名称：

  Synthesis of 24.xi.-Squalamine, an Anti-Infective Steroidal Polyamine

  摘要：

  Squalamine (1) is a novel steroidal polyamine which exhibits broad spectrum anti-infective activity. It inhibits the growth of bacteria, both Gram positive and Gram negative, and fungi. The synthesis of 24 xi-squalamine was accomplished in 17 steps from 3 beta-hydroxy-5-cholenic acid. The stereospecific introduction of the 7 alpha-hydroxyl group was achieved by allylic oxidation followed by hydrogenation of the Delta(5) olefin and reduction of the 7-keto group with K-selectride. The polyamine side chain was introduced via reductive amination of an appropriately functionalized 3-keto steroid with a suitably protected spermidine utilizing sodium cyanoborohydride as the reducing agent. The required 24-sulfate was introduced by selective sulfation of the 7 alpha,24 xi-diol with sulfur trioxide-pyridine complex.

  DOI：

  10.1021/jo00121a033

文献信息

• Methods for treating sleep disorders, sleep disturbances, and related symptoms using aminosterol compositions
  申请人：Enterin, Inc.

  公开号：US11083735B2

  公开（公告）日：2021-08-10

  This invention relates to methods of treating or preventing a sleep disorder, sleep disturbance, or related symptom in a subject with aminosterols or pharmaceutically acceptable salts or derivatives thereof. In particular, the disclosed methods generally comprise administering an aminosterol to a subject in need, thereby stimulating an aminosterol-induced CNS response to treat and/or prevent a sleep disorder, sleep disturbance, or related symptom.

  本发明涉及用氨甾醇或其药学上可接受的盐或衍生物治疗或预防受试者的睡眠障碍、睡眠紊乱或相关症状的方法。特别是，所公开的方法一般包括向有需要的受试者施用氨甾醇，从而刺激氨甾醇诱导的中枢神经系统反应，以治疗和/或预防睡眠障碍、睡眠障碍或相关症状。
• Aminosterol compositions and methods of using the same for treating schizophrenia
  申请人：Enterin, Inc.

  公开号：US11464789B2

  公开（公告）日：2022-10-11

  The present application relates generally to methods for treating, preventing and/or slowing the onset or progression of schizophrenia and/or a related symptom. The methods comprise administering at least one aminosterol or a pharmaceutically acceptable salt or derivative thereof to a subject in need.

  本申请一般涉及治疗、预防和/或减缓精神分裂症和/或相关症状的发生或发展的方法。这些方法包括向有需要的受试者施用至少一种氨甾醇或其药学上可接受的盐或衍生物。
• METHODS AND COMPOSITIONS FOR TREATING HALLUCINATIONS AND CONDITIONS RELATED TO THE SAME
  申请人：Enterin, Inc.

  公开号：US20190298740A1

  公开（公告）日：2019-10-03

  This application relates to methods of treating, preventing and/or slowing the onset or progression of hallucinations and/or related symptoms caused by a variety disorders, with aminosterols or pharmaceutically acceptable salts or derivatives thereof.
• METHODS OF TREATING ALZHEIMER'S DISEASE USING AMINOSTEROL COMPOSITIONS
  申请人：Enterin, Inc.

  公开号：US20200038412A1

  公开（公告）日：2020-02-06

  The present application relates generally to compositions and methods for treating, preventing, and/or slowing the onset or progression of Alzheimer's disease (AD) and a variety of symptoms related thereto with amino sterols or pharmaceutically acceptable salts or derivatives thereof.
• METHODS OF TREATING CARDIAC CONDUCTION DEFECTS USING AMINOSTEROL COMPOSITIONS
  申请人：Enterin, Inc.

  公开号：US20200038416A1

  公开（公告）日：2020-02-06

  The present application relates generally to compositions and methods for treating, preventing, and/or slowing the onset or progression of cardiac conduction defects (CCDs) and a variety of symptoms related thereto with amino sterols or pharmaceutically acceptable salts or derivatives thereof.